Replimune Group Inc

NASDAQ REPL

Download Data

Replimune Group Inc Long-Term Debt to Total Assets Ratio 2 year CAGR for the quarter ending March 31, 2024: 48.14%

Replimune Group Inc Long-Term Debt to Total Assets Ratio 2 year CAGR is 48.14% for the quarter ending March 31, 2024, a 192.54% change year over year. The long-term debt to total assets ratio measures the proportion of a company's long-term debt to its total assets. It is calculated by dividing the long-term debt by the total assets. This ratio indicates the extent to which a company's assets are financed by long-term debt. A higher ratio suggests a higher level of long-term debt relative to total assets, which can indicate increased financial risk and affect the company's ability to generate returns for its shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Replimune Group Inc Long-Term Debt to Total Assets Ratio for the quarter ending March 31, 2023 was 0.04.
  • Replimune Group Inc Long-Term Debt to Total Assets Ratio for the quarter ending March 31, 2020 was 0.04, a -1.52% change year over year.
NASDAQ: REPL

Replimune Group Inc

CEO Mr. Philip Astley-Sparke FSA
IPO Date July 20, 2018
Location United States
Headquarters 500 Unicorn Park Drive, Woburn, MA, United States, 01801
Employees 331
Sector Healthcare
Industry Biotechnology
Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Similar companies

UTHR

United Therapeutics Corporation

NA

NA

KURA

Kura Oncology Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

PRTC

PureTech Health PLC

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email